U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07090954) titled 'A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma' on July 21.
Brief Summary: The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: GR1803 injection
Participants will receive GR1803 injection.
DRUG: Anti-CD38 Monoclonal Antibody
Participants will receive anti-CD38 monoclona...